Kedar Drugs And Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 12-12-2024
- Paid Up Capital ₹ 2.50 Cr
as on 12-12-2024
- Company Age 2 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 11.00 Cr
as on 12-12-2024
About Kedar Drugs And Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 2.50 Cr.
The company currently has active open charges totaling ₹11.00 Cr.
Vimal Mehta, Parveen Kumar, and Puneet Kathuria serve as directors at the Company.
- CIN/LLPIN
U24290DL2022PTC395470
- Company No.
395470
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Mar 2022
- Date of AGM
30 Dec 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kedar Drugs And Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Puneet Kathuria  | Director | 01-Jul-2023 | Current |
| Vimal Mehta | Director | 24-Mar-2022 | Current |
| Parveen Kumar | Director | 24-Mar-2022 | Current |
Financial Performance of Kedar Drugs And Pharmaceuticals.
Kedar Drugs And Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Kedar Drugs And Pharmaceuticals?
Unlock access to Kedar Drugs And Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Brainwave Healthcare Private LimitedActive 16 years 7 monthsVimal Mehta and Parveen Kumar are mutual person
- Kedar Ayurveda Private LimitedActive 3 years 30 days
Vimal Mehta and Parveen Kumar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 13 Sep 2024 | ₹4.00 Cr | Open |
Others Creation Date: 20 Mar 2024 | ₹5.00 Cr | Open |
Others Creation Date: 20 Mar 2024 | ₹2.00 Cr | Open |
How Many Employees Work at Kedar Drugs And Pharmaceuticals?
Kedar Drugs And Pharmaceuticals has a workforce of 0 employees as of Apr 11, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kedar Drugs And Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kedar Drugs And Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
